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Abstract
Hepatitis C is an illness caused by the bloodborne Hepatitis C virus (HCV), and usually
becomes a chronic condition. Left untreated it can lead to severe liver disease and liver failure.
Newer treatments are effective and well tolerated, but most people with chronic HCV are not
accessing treatment due to several factors that will be discussed. The primary objectives of this
quality improvement (QI) project are to improve the treatment cascade, provide education to
providers and patients, and facilitate screening, virus confirmation, and referral to treatment, in a
Federally Qualified Health Center (FQHC).
Keywords: Hepatitis C, screening, linkage to care, primary care.
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Will Adding a Hepatitis C Screening Reminder in the EMR Along With Provider
Education Improve Screening, Confirmatory Testing, and Referral to the Treatment Care
Cascade?
Chapter 1 – Introduction
Background
Hepatitis C virus is the most common blood borne disease in New Mexico. As of 2018,
53,000 New Mexicans (about 2.5% of the population) had been exposed to HCV, most of whom
developed chronic infection (NM-IBIS, 2018). Treatment is available, but patients need to be
screened and treated in order to have an impact on this contagious and potentially deadly
infection.
Hepatitis C is an infection in the liver caused by the hepatitis C virus. Acute infections
range from mild to severe, and most often lead to a chronic infection. Chronic infections can lead
to liver fibrosis, cirrhosis, liver cancer, and liver failure. The U.S. Centers for Disease Control
and Prevention (CDC) has developed a strategy to eliminate HCV in the U.S. outlined in The
National Academy of Science, Engineering, and Medical Reports (NASEM) on Viral Hepatitis
(CDC, 2020). As of 2020, the current estimate of the number of individuals with chronic HCV in
the U.S. is 3.2 million (Healthy People 2020, n.d.). Healthy People 2030 has set goals of
decreasing deaths from HCV from 3.33/100,000 (rate from 2019) to 1.44/100,000. They have
also set a goal of decreasing the rate of HCV from 1/100,000 seen in 2017, to a target of
0.1/100,000. Lastly, they have set a goal of improving the percent of individuals cured of chronic
HCV infection from the 42.5% seen from 2013-16 up to a goal of 80% (ODPHP, n.d.).
Historically, the focus of screening was the Baby Boomer generation born between 19451965, but from 2010 to 2017, the incidence of HCV infection almost quadrupled. This was
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primarily due to injection drug use related to the opioid epidemic, and the rise in cases was seen
largely in the 20–39 years age group (CDC, 2017). In light of this, the U.S. Preventive Services
Taskforce (USPTF) (2020) has recommended universal one-time screening for all adults up to
age 79. This cost-effective strategy has proven robust in a variety of settings including
correctional, prenatal, primary care, and substance use treatment centers (Ghany & Morgan,
2020).
The advent of newer direct-acting antiviral medications has improved the treatment
landscape significantly. These newer medications are safe, well tolerated, and highly effective,
and have a greater than 95% cure rate (Falade-Nwulia et al., 2017). Elimination of HCV as a
public health threat is now conceivable. Key elements of the elimination plan include improved
identification of undiagnosed individuals, increased linkage and access to care for newly
diagnosed individuals, and expanded treatment access. Simplified treatment algorithms for those
who are treatment naïve and non-cirrhotic should ease treatment burden (CDC, 2020). The most
basic of treatment cascades includes: 1) documentation of HCV antibody, 2) patient notification
of result and availability of care, 3) viral load confirmation, 4) referral to treating provider and
staging of liver disease, 5) treatment medication received and taken, and 6) sustained virologic
response (cure) (Hachey et al., 2019).
New Mexico (NM) has been at the forefront of HCV treatment for many years. The
stated goal of the NM Hepatitis C Coalition is to prioritize the prevention, testing, and treatment
of HCV infection, in order to decrease the number of new infections, cure active infections, and
reduce the negative impact of the disease (Snow et al., 2016). As of 2018, NM had at least
53,000 individuals with HCV (2.5% of the population) (NM-IBIS, 2018). This number is about
the same as previous estimates from prior years. Though the treatment has become easier and
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more accessible, there are more patients contracting HCV, and linkage to treatment is less than
10% (Ghany & Morgan, 2020). Dr. Sanjeev Arora, from the University of New Mexico,
developed a program to extend HCV care into all of NM called Project ECHO (Extended
Community Healthcare Outcomes). Dr. Arora and his team have provided guidance to over 165
providers in NM and the U.S. that has allowed care to countless patients (Project ECHO, n.d.).
As proactive as NM has been, the number of untreated individuals with active infection is still
high. In order to decrease these numbers meaningfully, successful treatment regimens should be
provided to individuals with known infections, and undiagnosed cases should be identified and
referred to care.
Problem Statement
La Familia Medical Center (LFMC) is a Federally Qualified Health Center (FQHC) in
Santa Fe, NM. LFMC sees over 18,000 individual patients annually, over 14,000 of whom are
adults, and over 10,000 of whom live at or below the poverty level. Since 2018, 4529 individuals
18 years old and older have been screened for HCV (31% of the adult patient population), 320
(7%) of whom had a positive antibody test. Of those, 223 (70%) have had confirmatory testing,
with 142 having an active viral load (64% positivity rate). LFMC has identified a total of 315
patients as having active, untreated Hepatitis C (diagnosed but not treated), and has not yet
screened 69% of its current adult patient population. LFMC has an active Hepatitis C treatment
team consisting of one provider, one medical assistant, and one HCV Program Coordinator/
Navigator. All of the primary care providers (PCP) at the clinic are aware of the availability of
treatment on-site. Providers have been encouraged to universally screen patients for HCV
antibody but there had not been an electronic reminder. Reminders in the electronic medical
record (EMR) have been shown to increase the screening rate for HCV (Gemelas et al., 2016;
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Yakovchenko et al., 2019). If a patient is HCV antibody positive, a confirmatory test should be
ordered by the PCP, but this is not always done. The HCV navigator tracks these, and guides
patients through further testing once a referral is received from the PCP. If chronic HCV is
diagnosed, the navigator will refer to the HCV treating provider. Though this is not a formal
treatment cascade, it does informally address some of the steps of the cascade. Overall, about
203 patients have entered and completed treatment over the past 4 years.
This quality improvement project has been designed to increase patient screening and
formalize an HCV treatment cascade. Educating providers and implementing an EMR reminder,
providing HCV information to patients at the time of screening, and expediting confirmatory
testing should all help to optimize the process of identifying patients with chronic HCV. This
should lead to an increase in the number of patients referred to treatment.
PICOT Question
For adult patients at LFMC, will adding an HCV screening reminder in the EMR along
with provider education improve screening, confirmatory RNA testing, and referral rates to
benefit the HCV treatment care cascade for LFMC adult patients over 90 days in 2021, as
compared to 2020?
Objectives and Aims
The main objectives in this project are to get more patients screened for HCV, and to link
those with chronic HCV into the treatment cascade. To meet these objectives, I propose to
provide education to providers and patients, increase screening rate and confirmatory testing, and
have a referral process is place by:
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1. Having a reminder placed in the current EMR. If a patient has previously been tested,
the requirement is fulfilled, but if not, it will display an alert that will prompt the
provider to order screening.
2. Educating providers on current HCV screening recommendations, and assuring they
are aware of the EMR reminder.
3. Stressing the importance of a conversation about HCV screening with eligible
patients.
4. Providing HCV education to every person being screened, available in English and
Spanish (CDC handout).
5. Assuring positive antibody tests have confirmatory RNA testing done to assess for
chronic infection.
6. Advising patients and their providers of HCV status and referring for treatment when
indicated.
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Chapter 2 - Literature Review
Population Screening
HCV screening is ideally done through a person’s primary care provider (PCP), but has
been successful in a variety of settings (Ghany & Morgan, 2020). Using a public health approach
to identify and refer patients with chronic HCV has been successful in some larger cities, through
Community Health Centers, FQHCs, and syringe exchange programs. The public health model
was found to be effective in identifying, diagnosing, and linking individuals with chronic HCV
to care (Ford et al., 2018). Expanding the public health role to educate about risks and
treatments, reduce barriers, and provide support increased the number of individuals treated and
cured (Laraque et al., 2017). Frequently hospitals test for chronic HCV, but Sherbuk et al.
(2018) found that diagnosis during inpatient or ER visits had a much lower linkage to care rate
than those that were diagnosed in the outpatient setting.
Models to Improve Screening
HCV is the most common blood borne viral infection, but oftentimes screening is not
done. With the newer recommendation of universal HCV screening of all adults, getting more
patients screened presents a challenge. Integrating routine HCV testing into primary care as an
opt-out program has shown promise in increasing screening, confirmation of HCV, and linkage
to care (Coyle et al., 2016).
Many systems have implemented an EMR prompt for HCV screening. Several studies
have demonstrated a significant increase in HCV screening over the first year of implementation
(Konerman et al, 2017; Gemelas et al., 2016; Miller et al., 2016). Qualitative studies done after
the implementation of an EMR prompt showed the prompt to be the best cue for testing, and
most providers felt it was a helpful reminder and was not burdensome (Yakovchenko et al.,
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2019; Gemelas et al., 2016). A quality improvement project using the Plan-Do-Act Model
improved the outcome measures of HCV antibody screening, viral load confirmation, and
linkage to care (Bakhai et al., 2019).
Barriers and Facilitators to Screening
HCV screening is typically ordered by the PCP. There are many reasons why providers
do or don’t order screening. Often, providers are reluctant to offer screening or treatment if the
patient is still using alcohol or illicit substances, or has a history of mental illness (Yakovchenko
et al., 2019). But, Kim et al. (2018) found that having a substance use disorder or mental illness
did not affect a person’s ability to link to care. Providers were more prone to counsel patients on
HCV and to recommend screening and treatment if there was a known high disease burden in the
clinic setting (Gemelas et al., 2015, Miller, et al., 2016). Providers were also more prone to offer
screening and treatment if they were aware of the newer curative treatments, and if there were
support services in place, especially “treatment champions” (Yakovchenko et al., 2019).
The presence of treatment champions, care coordinators, project coordinators, nurse
navigators, and multidisciplinary teams had a strong association with increased screening and
linkage to care (Miller et al., 2016; Turner et al., 2019; Bakhai et al., 2019). Higashi et al (2020)
found that lack of knowledge and stigma play major roles in suboptimal screening.
Barriers and Facilitators to Linkage to Care
In 2016, the national rate for individuals with chronic HCV to be linked to care was 17%
(Reau et al., 2018). Barriers to linkage to care were patient and provider lack of knowledge
(Hachey et al., 2019) and race, with Blacks having the highest rate of HCV antibody positivity
and the lowest rate of linkage to care (Kim et al., 2018). Linkage to care was improved using a
nurse navigator model and enhanced patient tracking (Sherbuk et al., 2019; Coyle et al., 2016).
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Improved linkage to care has been demonstrated by using telemedicine, advanced practice
providers, established substance abuse services, and primary care clinics (Zuckerman et al.,
2018).
Special Concerns: Individuals Who Use Substances
The American Association for the Study of Liver Disease (AASLD) recommends at least
annual screening for individuals who are at increased risk of HCV exposure, such as those who
are currently injecting drugs, using illicit intranasal drugs, getting tattoos in an unregulated
setting, being incarcerated, and men who have unprotected sex with men (Ghany & Morgan,
2020). The National Institutes of Health (NIH) report that individuals who are actively injecting
illicit drugs are most severely affected by chronic HCV, but they are the least likely to receive
treatment. Several studies have shown successful HCV treatment in individuals actively injecting
drugs, when sufficient support services were in place (Edlin et al., 2007), and treatment of this
group is recommended by AASLD (2019).
The main barriers to treatment for persons who inject drugs (PWID) were lack of
knowledge, fear of treatment, cost of treatment, and insurance coverage. Facilitators to treatment
were availability of transportation, HCV treatment available at the same site, report from a friend
that HCV treatment had helped them, and having a friend or a partner who was concerned about
their chronic HCV infection (Falade-Nwulia et al., 2019). Individuals who misused substances
were more likely to link to care and complete treatment when linked to a clinic with embedded
support services (Sherbuk et al., 2018). Engaging PWID with mental health services and social
services increased uptake in HCV linkage to care and treatment (Zuckerman et al., 2018).
One of the most promising programs to engage PWID with treatment was the
Medication-Assisted Treatment (MAT) program, which uses buprenorphine to treat opioid
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dependence. For PWID, retention in MAT was associated with improved linkage to care, and
retention in treatment programs. The programs often provide patients with an opportunity to
access HCV treatment, which reduces transmission, morbidity, and mortality once the HCV is
treated (Norton et al., 2017).
Co-Located Clinic Sites
The last factor that had an effect on successfully linking patients to care was the location
of the treatment clinic. The availability of a co-located HCV treatment clinic likely contributed
to high linkage to care rates because patients were familiar with the clinic location, staff, and
operations. The presence of a treatment clinic on site also improved PCP familiarity with
treatment and improved the HCV exam in the primary care setting (Miller et al., 2016). FaladeNwulia et al. (2019) also noted in their qualitative study that treatment availability at the same
site was a facilitator to linkage to treatment. Coyle et al. (2019) performed a retrospective study
among five FQHCs, one of which was a “test and treat” site. They found that individuals with
chronic HCV were successfully linked to an HCV provider more often in the “test and treat” site
compared on average over the other clinical site types (81% vs 58%). They also stressed the
importance of adding HCV treatment services to HCV testing sites in order to improve access to
treatment.
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Chapter 3 – Methodology
Theoretical Model
The Model for Improvement (Appendix A) was developed by the Associates in Process
Improvement. It asks three fundamental questions about the desired change, which are
considered the “Aim” of the project, then incorporates the Plan Do Study Act (PDSA) cycle that
was developed by Edward Demings in 1950. The three questions are:
1) What are we trying to accomplish?
2) How will we know that a change is an improvement?
3) What change can we make that will result in improvement?
The PDSA cycle is illustrative for testing a change by “planning” it (P), “doing” it (D),
observing or “studying” the results (S), and “acting” on what is learned (A). By testing the
change on a smaller scale, one can easily assess if the change is beneficial, needs modification,
can be taken to a larger scale, or should be discarded (IHI, 2021). Bakhai et al. (2019)
successfully used the PDSA with nine cycles over a 24-month period to increase the screening
rate of HCV in their facility by 27%.
The Model for Improvement has been used by hundreds of health care organizations to
improve many different health care processes and goals. The aim of the project should be timespecific and measurable, and should define the affected population. Quantitative outcome and
process measures are plotted on a chart to see effects of the change quickly and easily over time
(IHI, 2021). The Model for Improvement is an ideal model for assessing effectiveness of QI
projects, as it includes visualization of change effects, and allows for modification of processes
as needed if the initial change is not effective.
Project and Study Design
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The aim of this project was to increase the number of eligible adult patients screened for
HCV, have confirmatory testing done if antibody positive, and have a referral for treatment in
place if chronic HCV was present. A change was an improvement if there was an increase in
screening by 10% over a three-month period, and if there was an increase in confirmatory testing
and referral for treatment when indicated. The placement of an EMR screening reminder,
provider education, and patient handouts should have lead to the desired improvement. The
PDSA cycle was used to monitor the effects of the change and to guide further improvement.
Setting and Resources.
This quality improvement project took place within La Familia Medical Center. LFMC is
an FQHC in Santa Fe, NM that serves over 18,000 individual patients annually, more than
10,000 of whom live at or below the poverty level. It is comprised of three sites: the main “Alto”
clinic, the “Southside” clinic, and the Healthcare for the Homeless clinic. LFMC is staffed by
MDs, FNPs, Pharmacists, Behavioral Health (BH) Therapists, Psychiatrists, Medical Assistants
(MAs), Case Managers, Community Health Workers (CHW), Lab Technicians, and Patient
Service Representatives. Services provided are primary care, specialty clinics, pharmacy, BH
support, MAT, and chronic HCV treatment. The group involved in implementing this QI project
included Maria McMahon FNP (lead), Lorie Martinez MA, Irene Berenstein CHW, and Ashley
Young IT support. For this QI project, I obtained data from all providers for a three-month
period in 2020 and again for a three-month period in 2021, after an educational intervention was
provided.
LFMC has a process in place to refer patients with chronic HCV to the CHW, who
provides HCV education, orders additional appropriate lab tests, and further refers patients to the
HCV provider (McMahon). Currently LFMC has screened about 31% of its adult population.
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There is a significant subset of patients who have had positive antibody testing but have not had
confirmatory testing, and another group of patients who have had positive confirmatory testing
but have not been referred for treatment consultation. For purposes of this project, I will not be
focusing on these subsets, but on screening patients who have not yet been screened. LFMC has
a dedicated staff to care for patients with chronic HCV.
Providers were given updated HCV training during a regularly scheduled monthly
provider meeting (discussed under Implementation). Patients were given an educational handout
when they were screened for HCV.
QI Project Population.
This QI project centered on adult patients (age 18 and over) within LFMC clinic who had
not yet been screened for HCV, and those individuals who were new patients establishing their
care at LFMC. Exclusion criteria were patient declination of the screening or treatment after
being counseled, previous negative screening in a low-risk patient not in need of rescreening, and
previous treatment of HCV. Pregnant women were not targeted, nor was pregnancy screened for,
for purposes of this project.
Sources of Data
Quantitative data was obtained from the LFMC EMR for a three-month period from July
1 – September 30, 2020, and for the same period again in 2021. Baseline patient data included
three months prior to the implementation of the EMR reminder (July – September 2020), looking
at the number of screenings done per number of eligible patients seen. Provider post-education
data included a three-month period obtained after IRB approval and full implementation of other
processes (provider education, patient handouts).
Ethical Considerations and Consent
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This QI project was submitted for initial application and had not previously been
reviewed by an Institutional Review Board (IRB); it was approved on June 14, 2021. There was
no specimen banking associated with this project. All data extracted was for patients age 18 and
older, and was de-identified. No drugs or devices were used for this project, and lab-work
obtained was standard of care.
The current USPTF (2020) screening guidelines have recently been expanded to include
HCV screening of all adults aged 18 to 79 who have not yet been screened. The standard of care
is to educate and recommend screening of all eligible adults. Patients consented to care when
they arrived in the clinic setting, so additional patient consent was not required. This QI project
served to bring the LFMC clinics up to the current standard of care.
Providers attended an educational session on HCV that was presented during a regularly
scheduled provider meeting. Using a PowerPoint presentation to educate providers can raise
awareness of the disease and increase screening rates (Bakhai et al., 2019).
Ethically, screening should be offered to every eligible person regardless of insurance
status, documentation status, language barriers, economic or educational disadvantage, mental or
physical disability, and those with current substance use. Learning of a positive HCV status may
cause increased anxiety for patients; this is often quelled by discussion of effective treatment
options. If patients continued to have anxiety and stress, they would be referred to BH, which
was readily available within LFMC.
As an FQHC, LFMC serves Santa Fe and the surrounding communities. Many patients
are considered to be part of a vulnerable population, with over 12,000 patients identifying as
Hispanic/Latino, and over 7,500 being non-English speakers. Through Spanish-speaking
providers or translation services, all non-English speakers should have been fully informed about
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screening recommendations and given the opportunity to consent to or decline screening.
Another vulnerable population within LFMC were those who used illicit drugs or had a history
of injection drug use. Many of them were identified through the MAT program, and this has been
an additional opportunity for screening. By educating patients and being as inclusive as possible,
LFMC has acknowledged the ethical principles of autonomy, beneficence, non-maleficence, and
justice. Once a patient has been diagnosed with chronic HCV and referred to care, there are
programs available to support treatment through the Department of Health, without cost to
eligible patients (those not otherwise eligible for Medicaid, Medicare, or commercial insurance).
Consent
A waiver of consent was requested from IRB. This project involved no more than
minimal risk to subjects. All data extracted was de-identified and there is no way to associate any
information to any patient or provider.
Patient chart data was obtained from all providers within LFMC for the designated time
periods. All providers in attendance at the regularly scheduled provider meeting received the
educational program as part of LFMC’s patient care improvement requirements.
Planning and Procedures
Planning
LFMC has an HCV treatment program in place and has screened about 31% of its
eligible adult population for HCV. Many of the current PCPs may not be aware of the current
screening guidelines, the effectiveness of the newer medications, or ease of the new treatment
protocols. This QI program was planned to increase the number of eligible patients being
screened for HCV, confirmed if antibody positive, and referred for treatment when appropriate.
The plan included addition of an EMR reminder for screening, and education of the providers
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with a PowerPoint presentation. The lab staff were to give any patient being screened an
informational handout on HCV results in their preferred language (only available in English and
Spanish). In turn, the providers should have educated their patients about the importance of HCV
screening, ordered the screening and confirmatory test if indicated, and referred them to
treatment if chronic HCV was present. LFMC management has been fully supportive of this
project and had suggested the team as outlined previously.
The aim of this project was to increase the number of patients being screened for HCV by
10% over a three-month period. A change in number of patients being screened for HCV was
assessed by comparing data pre- and post-implementation of changes.
Implementation
The reminder for HCV screening was recently placed on the EMR system, but LFMC
staff had not yet been educated on it. LFMC uses “eClinicalWorks” as their EMR. It provides a
tab for “Clinical Decision Support System”, or CDSS. The CDSS is an application that analyzes
data to support healthcare providers in making decisions to improve patient care (CDC, n.d.).
LFMC has incorporated HCV screening as a quality measure. The EMR screening reminder has
been shown to be the best cue for ordering the test, but providers need to be made aware of it
(Yakovchenko et al., 2019). The first process was to provide education to the providers via a
PowerPoint presentation during a regularly scheduled staff meeting. Provider education included
use of the new EMR reminder (Appendix B), and general HCV education.
The provider education session was well received. It was comprised of a review of HCV
including risks, prevalence, disease progression, and benefits of treatment. The roles of the PCP
in HCV treatment were reviewed including the screening guidelines, importance of counseling
on screening and risks, how to stage liver disease, when HCC surveillance is necessary, and how
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to recognize extrahepatic manifestations. An overview of HCV treatment was provided including
appropriate labs, available medications, and simplified treatment algorithms. Time was provided
for questions.
Patient handouts were available in the lab and in exam rooms. Any patient being screened
was to be given a handout that provided an overview of HCV and what the testing results mean
(Appendix C/D).
Method
This QI study was a retrospective chart review. It allowed for evaluation of improvement
using a PDSA cycle for three months, as compared to a three-month period prior to full
implementation. De-identified data was extracted by LFMC IT staff; study data were collected
and managed using REDCap electronic data capture tool hosted at UNM. Chart review was done
globally for all providers for the designated three-month period. De-identified data was extracted
from the LFMC EMR with queries for the number of patients seen who did not have prior
documentation of HCV screening, number of screening tests done (HCV antibody), number of
confirmatory tests (HCV viral load) done on positive antibody tests, and number of referrals for
treatment made for those with documented viral load. Using Pearson’s chi squared test and
Fisher’s exact test, a pre- and post-comparison was made. The pre- and post-populations were
adults within the LFMC clinic who had not yet been screened for HCV, seen by LFMC
providers. De-identified records were reviewed for the designated periods for lack of previous
HCV testing done, and if HCV testing was done on that visit. The denominator was the number
of eligible individuals (those without documentation of prior screening) seen during that time
period without duplications, the numerator was the number of HCV screening tests done. The
secondary comparisons made were those with positive antibody test getting confirmatory testing
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done (viral load), and those with chronic HCV (positive viral load) who were referred for
treatment.
Pearson’s chi square (x²) test is an inferential statistical test used to determine whether
two variables can be considered related “beyond a reasonable doubt”, and to evaluate if the
sample pattern is substantial enough so that it cannot be the result of sampling fluctuations. The
null hypothesis states that there is no difference between the two sampled groups, and if that
were true, the chi squared result would be zero (or close to zero). With one degree of freedom, a
chi squared value of 3.841 is significant (p = 0.05). The greater the chi squared result, the
stronger the significance level, indicating the observation is not random chance. Fisher’s exact
test is a similar test, also used for categorical data in a 2 by 2 table, when the cell numbers are
less than five (Stommel & Dontje, 2014).
An improvement was defined as an increase in screening of eligible patients by 10%.
Any increase in the number of confirmatory tests done and in the number of patients referred for
treatment would be seen as an improvement. Study power was obtained for the pre- and postscreening rates only, using Pearson’s chi squared test. The confirmatory and referral results were
evaluated with Pearson’s chi squared, or Fisher’s exact test for cells less than 5. Power analysis
statement: Assuming 4000 eligible patients in each time period and a baseline screening rate of
5%, this study will have sufficient statistical power (80%) to detect an increase in the proportion
of screened patients using Pearson’s chi squared test, if the intervention results in a screening
rate of at least 6.5% (B. Boursaw, personal communication, January 31, 2021).
Barriers and Facilitators
PCPs are continually faced with challenges of negotiating numerous care priorities with
limited time during patient visits. This process foreseeably required a few additional minutes of
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education by the provider, but it is standard of care to offer the screening. Patients were free to
decline the screening for any reason, but should make an educated decision to do so. Offering
HCV screening during regularly planned visits should have facilitated the process by
incorporating it into routine health care.
Prior to the COVID-19 pandemic, all patients were seen in person for HCV evaluation
and treatment. During the COVID-19 climate, LFMC had adopted scheduling most patients as
telehealth. This presented challenges in meeting face-to-face, in performing physical exams, and
in assuring lab work was done. Telehealth can be appropriate for otherwise healthy individuals,
and review of previous physical exam can be sufficient. It can lead to depersonalization of care
though, as most patients being treated for HCV are established with other providers for their
primary care, are being referred for treatment, and have most likely never met the HCV treating
provider. For patients with advanced liver disease this is not adequate, and they should have an
in-person exam. During the time of COVID-19, if a patient was not being seen in the clinic, (s)he
would need to go to the clinic for a lab draw; this may have deterred some individuals from
having it done. TH does have an advantage though: many patients can be treated for HCV by
TH, but that is beyond the scope of this project.
Another barrier was that many patients who need to be screened for HCV have poor
venous access due to past or present injection drug use. Having the rapid (finger stick) testing
available can be of great benefit. It allows for results in 15 minutes, and confirmatory testing can
be ordered right away instead of waiting for a send-out result and requiring the patient to return
for another lab draw. Unfortunately, that test has not been available at LFMC and LFMC is not
planning on making that test available.
Budget
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The activities undertaken for this QI project were consistent with requirements of the
UNM DNP program and were not billed to LFMC. The provider time allotted for the activity of
training was consistent with patient care improvement requirements of LFMC. The only
additional cost to the clinic was the cost of printing the handouts that were given to the patients
during the screening. The cost of the handouts was $7.00 per 100. There was no additional cost
to the patient above what they would ordinarily pay for the clinic visit, and for the test if they
were not insured or if they had a copay.
Timeline
The QI project was approved by the UNM College of Nursing and the UNM IRB on June
14, 2021. Provider education took place on July 7, 2021. After the training, data was extracted
for a three-month period (July, August, September) for 2020, and again for 2021. Analysis was
completed by December 31, 2021. The doctoral project was completed and defended on March
30, 2022.
This QI project served to standardize HCV screening within LFMC, educate providers
about HCV, and improve the referral process by identifying patients with chronic HCV.
Education of providers and patients plays a key role in improving this process. By maximizing
the capabilities of our treatment team, we can have a more profound impact on the health of our
patients, and on the long-term sequalae of HCV in our community.
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Chapter 4 – Results
This chapter presents the results of the data analyses including comparison of number of
eligible patients seen and screened during specified dates pre- and post-intervention. Data was
obtained from the LFMC EMR in de-identified, number only form. The number of patients seen
from July 1, through September 30, 2020 and July 1, through September 30, 2021 who had no
evidence of HCV screening documented on their chart was obtained. Data was also obtained to
reflect the number of screening tests that were done during the same time periods. For both
years, those numbers were reviewed to determine how many of the screening tests were positive,
and of those how many confirmatory tests (viral loads) were done. The number of positive viral
loads was verified, as well as the number of referrals made based on those positive results.
Pre-intervention
From July 1, through September 30, 2020 5,329 patients were seen who did not have
documented screening for HCV. 203 HCV screening tests were done, with 16 positive antibody
tests resulted. There were nine confirmatory tests ordered, resulting in seven positive viral loads.
five of those patients were referred for treatment.
Post-intervention
From July 1, through September 30, 2021 4,554 patients were seen who did not have
documented screening for HCV. 531 HCV screening tests were done, with 23 positive antibody
tests resulted. There were nine confirmatory tests ordered, resulting in seven positive viral loads.
six of those patients were referred for treatment.
Preliminary Analyses and Findings
The number of patients seen who did not have documentation for previous HCV
screening during both time periods, and number of HCV screening tests done during both time
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periods were evaluated using Pearson’s chi squared. The percent of positive antibody tests and
percent of confirmatory tests were also evaluated using Pearson’s chi squared. The percent of
positive viral loads and referrals made were evaluated using Fisher’s exact test. Pearson’s Chi
square and Fisher’s exact tests were done using GraphPad Prism version 9.3.0 for Windows,
GraphPad Software, San Diego, California USA, www.graphpad.com.
The number of patients screened for HCV significantly increased after the intervention.
x²(1, 9,883) = 220.13, p < 0.0001. It can be concluded that there was a positive relationship for
the number of patients screened after the interventions took place, compared to the prior year.
In 2020, 5329 patients were seen who did not have previous documentation for HCV
screening. 203 HCV screening tests were done, which is a screening rate of 3.8%. In 2021, 4554
patients were seen who did not have previous documentation for HCV screening. 531 HCV
screening tests were done, which is a screening rate of 11.7%. There was an improvement of 7.9
percentage points, which reflects a 3-fold increase in the amount of testing done (x² = 220.13, p <
0.0001). The percentage of positive antibody tests was lower in the post-intervention period
(7.9% versus 4.3%), but was not statistically significant, x²(1, 734) = 3.68, p = 0.06. The
percentage of confirmatory tests ordered was also lower post-intervention (56% versus 39%), but
was not statistically significant, x²(1, 39) = 1.11, p = 0.29. The percentage of positive viral loads
was identical pre- and post-intervention, (78%, p > 0.99). The percentage of referrals made was
improved post-intervention (71% versus 86%, p > 0.99); this was not statistically significant, but
it did meet the project goal of improving.
Evaluations and Outcomes
In 2021, post-intervention, there were fewer patients seen who did not have
documentation of previous testing, but there were significantly more screening tests ordered. It
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can be assumed that providing provider education improved the provider screening behavior,
though these results are still very far from the universal screening recommendation. The
percentage of positive antibody tests was lower, but this corresponded with previous studies that
increase the number of eligible individuals being screened by encouraging universal screening
(Konerman, et al., 2017). There was a decrease in the percentage of confirmatory tests done, but
it is unclear why. It could be due to the current COVID-19 pandemic or to provider turnover, it
will be discussed further in the discussion chapter. The percentage of positive viral loads was
unchanged. The number of individuals referred for treatment was improved and met the project
goals, but the low numbers did not provide for significance.
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Chapter 5 – Discussion
This quality improvement project, using quantitative methods, sought to assess
improvement of Hepatitis C screening, confirmation, and referral for treatment within La Familia
Medical Center by implementing a reminder in the EMR and providing education to providers
and patients.
Key Findings
The findings demonstrated an improvement in provider behavior in ordering screening
tests, but there was not significant improvement in confirmatory tests done, or in referrals made.
The outcomes of this project indicate that adding an EMR reminder and providing provider
education is an effective approach to increase the number of patients screened for HCV.
A surprising finding was the decrease in number of confirmatory tests done. One of the
factors that could influence this result is a recent increase in provider turnover. During July
through September 2021, LFMC had a turnover of five of 14 providers. These providers were
present for the educational session, but left the organization prior to completion of the threemonth evaluation period. This may have led to lack of follow-up, and it placed an additional
burden on the remaining providers until new providers were brought in and oriented to the
LFMC system. Another factor could be the current COVID-19 environment, which presented
barriers to being seen in the clinic and having further testing done, but COVID-19 was also
present during the previous data collection period. Perhaps the recent COVID-19 variants
affected personal behavior and mobility, but investigation of that was beyond the scope of this
project.
The Model for Improvement using a PDSA cycle was helpful in integrating this quality
improvement project. The project aim was to increase the number of eligible patients screened
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for HCV, have confirmatory testing done if antibody positive, and have a referral for treatment in
place if chronic HCV was present. An improvement was defined as an increase in screening by
10% over a three-month period, an overall increase in confirmatory testing, and referral for
treatment if virus was present.
A significant increase in HCV screening tests was seen post-intervention, from 3.8% of
eligible patients screened during the 2020 period to 11.7% during the 2021 period. This is an
improvement of 7.9 percentage points; a three-fold increase in the amount of screening done.
The decrease in antibody positivity rate is likely due to the increased screening (universal versus
risk-factor focused) and has been seen in previous studies that sought to implement universal
HCV screening. When universal screening is implemented, it includes not only those at
increased risk of HCV infection but also those with low or average risk. This often leads to a
decrease in the positivity rate (Konerman et al., 2017; Zuckerman et al., 2017). It is not clear
why there was a decrease in the number of confirmatory tests done, but as discussed previously it
may be due to increased provider turnover and the current COVID-19 variant environment.
The lack of confirmatory testing should be much less of an issue going forward as LFMC
has recently adopted an HCV lab test that includes reflex testing. This new test has been
available through Tricore since December 15, 2021; it provides for reflex viral load
(confirmatory testing) with the same blood draw if the antibody is present. Use of reflex testing
has been shown to significantly improve diagnosis rates and to decrease omitted viral load
testing up to 76%. It requires fewer provider visits and fewer blood draws (Lopez-Martinez et al,
2020). LFMC contracts with Tricore for laboratory services. which provides the new HCV
antibody and reflex test (HCVDX). The cost of the test is covered through insurance, but for
those without insurance the cost is $14.25 for the antibody portion, and an additional $215.85 if
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the reflex test is done. This can be cost prohibitive for an uninsured patient, so some providers
will still opt to order the basic HCV antibody test, which costs $18.00 (I. Martinez, personal
communication, January 25, 2022).
This project reflects the improvement in screening that was observed by Konerman et al.
(2017) and Miller et al (2016) when they implemented an EMR prompt for HCV screening. The
EMR reminder in the LFMC system was introduced a couple of months prior to the provider
education session, but providers were largely unaware of it. Providing education to the providers
seemed to increase the number of screening tests done, as was also shown by Miller et al. and
Gemelas et al (2016). All of the studies that tracked patients through a treatment cascade showed
a significant drop-off of patients along each step of the cascade, but the lack of confirmatory
testing seen here post-intervention was the most significant. None of the studies reviewed had
automatic reflex testing for HCV confirmation, and it will be interesting to see going forward
how this is affected. As Gemelas et al. reported, the higher screening rate also allows the clinic to
have a better understanding of the disease burden in the community.
Implications
The current recommendation from the USPTF, CDC and AASLD is to screen all patients
age 18 to 79 for HCV once (annually for those with risk factors). This project demonstrated that
more patients can be screened when providers are informed of current guidelines,
recommendations and treatment regimens. Providers face constant challenges in providing
recommended screenings, but having a reminder in the EMR can reinforce current
recommendations. The recently updated option to order the diagnostic HCV testing, which
includes the reflex viral load when the antibody is positive, will decrease the number of patient
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visits and lab draw orders. This should improve the number of confirmatory tests done and
simplify movement along the treatment cascade.
With the recent increase in provider turnover, new providers should be educated on the
current screening recommendations, and on accessing the patient screening prompts in the EMR.
New providers should be aware of on-site availability of HCV treatment and the referral process.
Maintaining this standard of care can have meaningful implications for patient health and
community health.
The policies of LFMC should be continually updated to include the standard of care. In
particular, updates should include the changes in reflex testing, and program availability for
patients who are not eligible for insurance (specifically the undocumented).
Future Research
This QI project was done during a time of COVID-19, and prior to availability of reflex
testing. If COVID-19 ever becomes a non-issue, it would be interesting to assess improvement of
diagnosis and movement along the treatment cascade. Recent research by Lopez-Martinez et al.
(2020) has shown significant improvement in diagnosis of chronic HCV with reflex testing. With
the current low confirmatory testing numbers, it would be helpful to assess if the use of reflex
testing increases the number of individuals diagnosed with chronic infection.
One factor in ordering HCV testing is lack of patient insurance. Looking at whether
providers neglect to order tests due to lack of insurance would be a helpful indicator moving
forward. DOH has options for HCV screening that will not incur patient cost, but LFMC is not
accessing those programs. Closer partnership with DOH may avail LFMC to those programs,
and improve patient screening especially for those not eligible for insurance coverage.
Sustainability of Practice Change
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Providers who were employed at the time of the educational intervention were informed
on current recommendations, standards of care, treatment protocols, and the EMR prompt. New
providers should be updated on this as well, and a presentation is being scheduled for new
residents coming into LFMC. Universal screening is standard of care, and the hope is that this
program will continue to improve compliance.
LFMC currently has an HCV treatment team, but only one provider who offers treatment.
All providers have been offered treatment training, but there has not been uptake with the current
providers. It is important to have a treatment champion within the clinic for consultations and
recommendations, and LFMC does plan to continue that position. With the new simplified
treatment algorithms, it is the hope that more providers will be amenable to provide treatment. A
limitation of this project is that it focuses on early components the HCV care cascade with
screening, confirmation, and referral to treatment. It does not include treatment. Within these
parameters, it is the hope that providers will continue to improve on the universal screening
goals. It is reasonable to envision annual updates and reminders on HCV screening and
treatment, as it is a quality measure within LFMC. Once a patient has been diagnosed, (s)he can
typically be scheduled with the treatment provider within 2 weeks. If the current treating
provider would not be available, LFMC would need to find another treating provider.
Limitations
There were several limitations to this study. Most retrospective studies evaluated data for
a one- to three-year period, this study evaluated data for only three months. This QI project was
done within a three-clinic FQHC that serves a population that is largely Latino and in an underserved community. It was also done during the COVID-19 pandemic, which has resulted in
limited clinic access and patient mobility. The relatively low antibody positivity rate could be
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related to selection of individuals being screened, i.e., screening may not have been ordered if
the patient was uninsured (which was not evaluated in this study). Another limitation was the
unexpected increase in provider turnover during the 2021 evaluation period.
This study could be generalized to FQHCs that serve a similar population. Data collection
was felt to be valid, as it was done by one person with standardized measurements. Data was
analyzed using a validated tool, with the guidance of a statistician.
Conclusion
Chronic HCV is a potentially devastating disease that is easily treated when it is caught
early. Because it frequently does not have symptoms early on, universal screening of all adults is
an effective way to identify asymptomatic patients. Vigilant monitoring of all birth cohorts,
including the younger cohorts that have had increased incidence of chronic HCV, will help us
meet the Healthy People 2030 goal of eliminating HCV as a public health problem. Improvement
in accurate and comprehensive reporting trends in population-based screening are warranted to
help us meet that goal (Bian, J, & Schreiner, A., 2019).
The outcomes of this project reinforce the importance of keeping providers up to date on
current screening recommendations and availability of effective treatments. Only in identifying
individuals infected with chronic HCV and treating them before complications arise, can we
have a significant impact on this public health problem.
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Appendix A
Theoretical Model Diagram
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